Advertisement
Screener

SILEXION THERAPEUTICS CORP (SLXN) Overview

SILEXION THERAPEUTICS CORP (SLXN) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual 5.17; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual 8.46; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual 2.88; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual 43.19; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$0.24$0.66$1.87$5.28$14.89$42.002025-09-292026-09-29$0.24$1.43$8.67$52.62$319.29$1,937.252021-09-292026-09-29$0.24$1.43$8.67$52.62$319.29$1,937.252021-04-072026-09-29$0.24$1.43$8.67$52.62$319.29$1,937.252021-04-072026-09-29$0.24$1.43$8.67$52.62$319.29$1,937.252021-04-072026-09-29

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$0.32
Previous close
$0.25
Change
$0.07
Change (%)
28.23%
Close date
2026-09-29
Previous close date
2026-09-28
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

SLXN
-98.34%
S&P 500
(m)

1 year

SLXN
-99.06%
S&P 500
(m)

3 years

SLXN
-99.98%
S&P 500
(m)

5 years

SLXN
-99.98%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual 5.17

2.8012.9423.0933.2343.3731 Mar 2025: estimate (m); actual 38.3931 Mar 2025(m)30 Jun 2025: estimate (m); actual 43.1930 Jun 2025(m)30 Sept 2025: estimate (m); actual 2.8830 Sept 2025(m)31 Mar 2026: estimate (m); actual 8.4631 Mar 2026(m)30 Jun 2026: estimate (m); actual 5.1730 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)5.17(m)(m)
1 Jan 202631 Mar 2026(m)8.46(m)(m)
1 Jul 202530 Sept 2025(m)2.88(m)(m)
1 Apr 202530 Jun 2025(m)43.19(m)(m)
1 Jan 202531 Mar 2025(m)38.39(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual 89.61

89.531055.972022.412988.853955.2931 Dec 2023: estimate (m); actual 659.5531 Dec 2023(m)31 Dec 2024: estimate (m); actual 3955.1131 Dec 2024(m)31 Dec 2025: estimate (m); actual 89.6131 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)89.61(m)(m)
1 Jan 202431 Dec 2024(m)3955.11(m)(m)
1 Jan 202331 Dec 2023(m)659.55(m)(m)

Revenue vs. Earnings

USD

No complete retained periods.

No complete retained periods.

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$0.32(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$0.32High(m)Average(m)Low(m)2025-09-292026-09-29

Recent news

View more →

(m)

YouTube videos mentioning SLXN

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-12; financial period ending (m).

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
(m)
Profit margin
(m)
Return on assets · 12 month
(m)
Stock compensation expense · all employees · 12 months
(m)
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
(m)
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
29.81M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-18.88%*
Total return · month
-12.40%*
Total return · quarter
-87.63%*
Total return · half year
-97.39%*
Total return · year to date
-98.34%*
Total return · 1 year
-99.06%*
Total return · 3 years
-99.98%*
Total return · 5 years
-99.98%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
(m)
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

SILEXION THERAPEUTICS CORP Overview

View more →

(m)

(m)

SEC CIK
2022416
Industry (SIC)
2836 Biological Products, (No Diagnostic Substances)
Country of operation
(m)
Business address
12 ABBA HILLEL ROAD, RAMAT GAN, 5250606
Fiscal year end
1231
Phone
972-8-6286005

Similar stocks

Stock NameCountryMarket CapPE Ratio
CURIS INC (CRIS)United States$0.002B-0.05
Calidi Biotherapeutics, Inc. (CLDI)United States$0.003B
VivoSim Labs, INC. (VIVS)United States$0.003B
WINDTREE THERAPEUTICS INC /DE/ (WINT)United States$0.003B-0.32
PharmaCyte Biotech, Inc. (PMCB)United States$0.005B
AIM ImmunoTech Inc. (AIM)United States$0.006B
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ)United States$0.006B
CERO THERAPEUTICS HOLDINGS, INC. (CERO)United States$0.007B
TScan Therapeutics, Inc. (TCRX)United States$0.008B-1.23
Senti Biosciences Holdings, Inc. (SNTI)United States$0.011B-0.70